Profound Medical Corp.
PROF | NASDAQ
$6.12
+$0.02 (+0.33%)
Sep 22, 2026, 11:44 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 16.38M | 10.17M | 7.2M | 6.68M | 6.87M | 7.3M |
Cost of Revenue | 4.79M | 3.47M | 2.82M | 3.66M | 3.92M | 3.83M |
Gross Profit | 11.59M | 6.7M | 4.38M | 3.02M | 2.95M | 3.47M |
Operating Income | -41.98M | -31.47M | -28.62M | -32.13M | -30.29M | -18.86M |
Interest Income | 1.09M | 1.37M | 1.64M | 1.05M | 203.2K | 692K |
Pretax Income | -43.06M | -26.48M | -28.7M | -28.38M | -30.59M | -21.58M |
Net Income | -43.32M | -26.48M | -28.57M | -28.67M | -30.7M | -21.62M |
Selling & General & Admin | 32.61M | 22.02M | 18.62M | 17.93M | 17.97M | 12.43M |
Research & Development | 20.96M | 16.15M | 14.38M | 14.69M | 15.28M | 9.91M |
Other Expenses | n/a | n/a | n/a | 2.52M | n/a | n/a |
Operating Expenses | 53.57M | 38.17M | 33M | 35.15M | 33.24M | 22.34M |
Interest Expense | n/a | n/a | 770K | 167.11K | 66.41K | 543K |
Selling & Marketing Expenses | n/a | n/a | 9.45M | 8.47M | 7.65M | 4.86M |
Cost & Expenses | 58.36M | 41.64M | 35.82M | 38.81M | 37.16M | 26.17M |
Income Tax Expense | 256.41K | -1.9K | -128K | 287K | 105K | 45K |
Shares Outstanding (Basic) | 30.23M | 24.77M | 21.18M | 20.83M | 20.46M | 17.29M |
Shares Outstanding (Diluted) | 30.23M | 24.77M | 21.18M | 20.83M | 20.47M | 17.29M |
EPS (Basic) | -1.43 | -1.07 | -1.35 | -1.38 | -1.50 | -1.25 |
EPS (Diluted) | -1.43 | -1.07 | -1.35 | -1.38 | -1.50 | -1.25 |
EBITDA | -41.41M | -25.59M | -26.78M | -26.6M | -28.65M | -19.5M |
EBIT | -41.98M | -26.48M | -27.93M | -28.21M | -30.53M | -21.03M |
Depreciation & Amortization | 569.8K | 891.06K | 1.15M | 1.6M | 1.88M | 1.54M |
Add to Watchlist
Select watchlists to add or remove PROF